# Study of DAXDILIMAB for the Treatment of Moderate-to-Severe Alopecia Areata

> **NCT05368103** · PHASE2 · COMPLETED · sponsor: **Amgen** · enrollment: 30 (actual)

## Conditions studied

- Alopecia Areata

## Interventions

- **BIOLOGICAL:** Daxdilimab

## Key facts

- **NCT ID:** NCT05368103
- **Lead sponsor:** Amgen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-04-27
- **Primary completion:** 2023-08-07
- **Final completion:** 2024-01-26
- **Target enrollment:** 30 (ACTUAL)
- **Last updated:** 2025-01-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05368103

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05368103, "Study of DAXDILIMAB for the Treatment of Moderate-to-Severe Alopecia Areata". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT05368103. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*